在2026年AACR会议上,OBI Pharma 发布了新一代抗体药物联合剂的GlycOBI平台. OBI Pharma presents GlycOBI platform for next-gen antibody-drug conjugates at 2026 AACR meeting.

欧比制药公司在2026年美国抗体研究会年度会议上宣布了10个海报展示,突出显示其下一代抗体-药物结合物的GlycOBI平台. OBI Pharma announced ten poster presentations at the 2026 AACR Annual Meeting highlighting its GlycOBI platform for next-generation antibody-drug conjugates. 该公司展示了针对TROP2,Nectin-4和双重点的首选药物,证明其改善的药理动力学以及克服耐药性的能力. The company showcased lead candidates targeting TROP2, Nectin-4, and dual targets, demonstrating improved pharmacokinetics and the ability to overcome drug resistance. 特定位点的结合技术旨在提高稳定性并减少非标毒性,从而实现更安全的癌症治疗. Site-specific conjugation technology aims to enhance stability and reduce off-target toxicity for safer cancer treatments.